Global Hereditary Angioedema Therapeutic Market Size By Type (Intravenous, Subcutaneous), By Application (Hospitals, Clinics), By Region, And Segment Forecasts, 2023 to 2032

The Global Hereditary Angioedema (HAE) Therapeutic Market was valued at USD 3.2 billion in 2023 and is projected to surpass USD 7.9 billion by 2031, growing at a CAGR of 12.4% during the forecast period from 2023 to 2031. The rising incidence of HAE, increased awareness of rare diseases, advancements in genetic research, and growing access to advanced biologic therapies are key drivers propelling market growth. Hereditary Angioedema, a rare genetic disorder characterized by recurrent swelling, can be life-threatening if not properly managed. Improved diagnostic capabilities and evolving treatment landscapes have expanded therapeutic options, thus improving quality of life for patients globally.

Drivers

1. Increasing Prevalence of Hereditary Angioedema

The global rise in diagnosed cases of HAE, partly due to improved screening and awareness initiatives, is contributing to the market's expansion. As more patients are identified early, demand for long-term prophylactic and acute therapies increases.

2. Growth in Biologic Drug Development

Biologics, including monoclonal antibodies and plasma-derived therapies, have significantly improved efficacy and safety outcomes in HAE treatment. Innovations like lanadelumab and berotralstat have transformed patient management, spurring pharmaceutical investment.

3. Awareness and Advocacy

Increased efforts by patient advocacy groups and healthcare bodies to promote early diagnosis and better access to treatment are fueling market growth, especially in developed economies.

Restraints

1. High Cost of Therapy

The annual cost of HAE medications remains high, especially for novel biologics. This cost burden is a significant barrier in lower-income and middle-income countries where healthcare infrastructure and insurance systems may be underdeveloped.

2. Limited Availability in Developing Markets

Therapeutic options for HAE are not universally accessible due to distribution limitations and lack of reimbursement policies, especially in emerging economies. This restricts the global reach of key therapies.

Opportunity

1. Pipeline Advancements and Gene Therapy

The HAE treatment pipeline includes gene-editing technologies aimed at permanent cures, offering transformative potential. Investment in such innovations by key market players indicates long-term growth prospects.

2. Expansion in Emerging Markets

Increasing healthcare infrastructure development and pharmaceutical partnerships in Asia-Pacific, Latin America, and the Middle East & Africa open new markets for HAE therapies.

Market by System Type Insights

By treatment type, the Prophylactic Treatment segment accounted for the largest market share in 2023. Innovations in long-term preventative therapies, including kallikrein inhibitors and monoclonal antibodies, have improved disease management and reduced attack frequency, driving patient preference toward this segment. Meanwhile, On-demand Therapy is growing steadily as acute treatment remains essential for unplanned HAE attacks.

Market by End-use Insights

The Hospital & Specialty Clinics segment led the market in 2023, holding over 60% of the revenue share. This dominance is due to the need for specialized diagnostic and therapeutic services. Increasing use of home-based treatment settings is emerging as a fast-growing segment, supported by self-administered therapies and digital health platforms.

Market by Regional Insights

North America dominated the global HAE therapeutic market in 2023, fueled by high diagnosis rates, robust healthcare infrastructure, and wide availability of advanced therapeutics. Europe follows closely, driven by proactive healthcare policies and strong pharmaceutical pipelines. The Asia-Pacific region is projected to grow at the highest CAGR, supported by rising healthcare expenditure, patient awareness, and ongoing regulatory improvements in countries like China and India.

Competitive Scenario

Key players in the Global Hereditary Angioedema Therapeutic Market include:

Takeda Pharmaceutical Company Limited

CSL Behring

Pharming Group N.V.

BioCryst Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc.

Attune Pharmaceuticals

KalVista Pharmaceuticals

Adverum Biotechnologies

Intellia Therapeutics

Genentech (Roche)

Companies are actively pursuing R&D strategies, regulatory approvals, and geographic expansion to solidify their presence. For instance:

In 2024, BioCryst Pharmaceuticals received FDA approval for expanded use of berotralstat in pediatric patients.

In 2023, Takeda launched new real-world data programs to evaluate lanadelumab’s long-term impact.

In 2022, CSL Behring expanded its plasma fractionation facility in Germany to boost supply capacity.

Scope of Work – Global Hereditary Angioedema Therapeutic Market

Key Market Developments

March 2025: Ionis Pharmaceuticals initiated a phase 3 clinical trial for its novel antisense oligonucleotide for HAE prophylaxis.

September 2024: KalVista Pharmaceuticals received EMA orphan drug designation for its oral kallikrein inhibitor.

June 2023: Pharming Group expanded distribution partnerships in Southeast Asia to increase drug accessibility.

FAQs

1) What is the current market size of the Global Hereditary Angioedema Therapeutic Market?

The market was valued at USD 3.2 billion in 2023.

2) What is the major growth driver of the Global Hereditary Angioedema Therapeutic Market?

Key growth drivers include increased disease awareness, improved diagnostic capabilities, and biologic drug innovations.

3) Which is the largest region during the forecast period in the Global Hereditary Angioedema Therapeutic Market?

North America is expected to remain the dominant region, followed by Europe.

4) Which segment accounted for the largest market share in the Global Hereditary Angioedema Therapeutic Market?

The Prophylactic Treatment segment held the largest market share in 2023.

5) Who are the key market players in the Global Hereditary Angioedema Therapeutic Market?

Key players include Takeda, CSL Behring, BioCryst, Pharming Group, and Ionis Pharmaceuticals.